Administration of combined venetoclax and azacitidine in a patient with acute myeloid leukemia and multiple comorbidities undergoing dialysis: A case report

被引：0
|
作者：
Akagi, Yuina [1 ,2 ]
Yamashita, Yusuke [1 ,2 ]
Kosako, Hideki [1 ]
Furuya, Yoshiaki [1 ,2 ]
Hosoi, Hiroki [1 ]
Mushino, Toshiki [1 ]
Murata, Shogo [1 ]
Nishikawa, Akinori [1 ]
Tamura, Shinobu [1 ]
Nakao, Taisei [2 ,3 ]
Sonoki, Takashi [1 ]
机构：
[1] Wakayama Med Univ, Dept Hematol Oncol, 811-1 Kimiidera, Wakayama, Wakayama 6418509, Japan
[2] Naga Municipal Hosp, Dept Hematol, Wakayama, Japan
[3] Naga Municipal Hosp, Dept Internal Med, Wakayama, Japan
来源：
EJHAEM | 2023年 / 4卷 / 03期
关键词：
acute myeloid leukemia; azacitidine; dialysis; venetoclax; OLDER PATIENTS; PHARMACOKINETICS; 5-AZACYTIDINE; CARE;
D O I：
10.1002/jha2.732
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Patients with acute myeloid leukemia (AML) who have comorbidities have limited treatment options, thereby resulting in poor prognosis. Venetoclax, a specific B-cell lymphoma-2 inhibitor, has recently been approved for AML in combination with hypomethylating agents; however, only one report has described its use in patients undergoing dialysis. Herein, we report the effectiveness of combined venetoclax and azacitidine in a 73-year-old man with AML undergoing dialysis and who was ineligible for standard therapies. The safety of venetoclax and azacitidine in patients undergoing dialysis has been reported, and their combination may be a feasible option for patients with AML undergoing dialysis.
引用
收藏
页码：841 / 843
页数：3
相关论文
共 50 条
  • [1] Leukemia Cutis in a Patient with Acute Myeloid Leukemia Undergoing Azacitidine-Venetoclax: Case Presentation and Review of the Literature
    Buzzatti, Elisa
    Mauro, Cristina
    Botti, Caterina
    Presicci, Roberta
    Paterno, Giovangiacinto
    Palmieri, Raffaele
    Gurnari, Carmelo
    Mallegni, Flavia
    Meddi, Elisa
    Moretti, Federico
    Cardillo, Lucia
    Mezzanotte, Valeria
    Taka, Kristian
    De Marchi, Lucrezia
    Maurillo, Luca
    Buccisano, Francesco
    Venditti, Adriano
    del Principe, Maria Ilaria
    MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2025, 17 (01)
  • [2] Azacitidine and venetoclax with or without pevonedistat in patients with newly diagnosed acute myeloid leukemia
    Short, Nicholas J.
    Wierzbowska, Agnieszka
    Cluzeau, Thomas
    Laribi, Kamel
    Recher, Christian
    Czyz, Jaroslaw
    Ochrem, Bogdan
    Ades, Lionel
    Gallego-Hernanz, Maria Pilar
    Heiblig, Mael
    Audisio, Ernesta
    Zarzycka, Ewa
    Li, Shuli
    Ferenc, Nicholas
    Yeh, Tammie
    Faller, Douglas V.
    Sedarati, Farhad
    Papayannidis, Cristina
    LEUKEMIA & LYMPHOMA, 2025, 66 (03) : 458 - 468
  • [3] Successful combination treatment with azacitidine and venetoclax for a patient with acute myeloid leukemia undergoing hemodialysis
    Edahiro, Taro
    Ureshino, Hiroshi
    Chishaki, Ren
    Fujino, Keita
    Mino, Tatsuji
    Yoshida, Tetsumi
    Fukushima, Noriyasu
    Ichinohe, Tatsuo
    LEUKEMIA & LYMPHOMA, 2022, 63 (14) : 3511 - 3512
  • [4] Case report: Venetoclax plus Azacitidine in treatment of acute undifferentiated leukemia
    Cui, Yu
    Mi, Ruihua
    Chen, Lin
    Wang, Lin
    Li, Dongbei
    Wei, Xudong
    HEMATOLOGY, 2024, 29 (01)
  • [5] The Clinical Tumor Lysis Syndrome in a Patient with Mixed Phenotype Acute Leukemia Undergoing Induction with Venetoclax and Azacitidine: A Case Report
    Drozd-Sokolowska, Joanna
    Madry, Krzysztof
    Siewiorek, Kinga
    Feliksbrot-Bratosiewicz, Magdalena
    Stoklosa, Tomasz
    Gierej, Beata
    Stefaniak, Agnieszka
    Paszkowska-Kowalewska, Malgorzata
    Sokolowski, Jacek
    Sankowski, Bartlomiej
    Basak, Grzegorz Wladyslaw
    CHEMOTHERAPY, 2022, 67 (03) : 173 - 177
  • [6] Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy
    Yamamoto, Kazuhito
    Shinagawa, Atsushi
    DiNardo, Courtney D.
    Pratz, Keith W.
    Ishizawa, Kenichi
    Miyamoto, Toshihiro
    Komatsu, Norio
    Nakashima, Yasuhiro
    Yoshida, Chikashi
    Fukuhara, Noriko
    Usuki, Kensuke
    Yamauchi, Takahiro
    Asada, Noboru
    Asou, Norio
    Choi, Ilseung
    Miyazaki, Yasushi
    Honda, Hideyuki
    Okubo, Sumiko
    Kurokawa, Misaki
    Zhou, Ying
    Zha, Jiuhong
    Potluri, Jalaja
    Matsumura, Itaru
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2022, 52 (01) : 29 - 38
  • [7] Durable remission of acute myeloid leukemia in an elderly patient following a limited course of azacitidine and venetoclax
    Ehsan, Hamid
    Iqbal, Qamar
    Masood, Adeel
    Grunwald, Michael R.
    LEUKEMIA RESEARCH REPORTS, 2022, 18
  • [8] Single-institution experience of venetoclax combined with azacitidine in newly diagnosed acute myeloid leukemia patients
    Yu, Hong
    Wang, Chaomeng
    Lei, Yingying
    Li, Lijuan
    Wang, Huaquan
    Wang, Guojin
    Xing, Limin
    Guan, Jing
    Song, Jia
    Wu, Yuhong
    Liu, Hong
    Qu, Wen
    Wang, Xiaoming
    Shao, Zonghong
    Fu, Rong
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 127
  • [9] Benefit of the Reduced Dose Combination of Azacitidine and Venetoclax in an Elderly Patient With Acute Myeloid Leukemia
    Fujino, Keita
    Ureshino, Hiroshi
    Yoshida, Tetsumi
    Ichinohe, Tatsuo
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (05)
  • [10] Venetoclax with decitabine or azacitidine in relapsed or refractory acute myeloid leukemia
    Bouligny I.M.
    Murray G.
    Doyel M.
    Patel T.
    Boron J.
    Tran V.
    Gor J.
    Hang Y.
    Alnimer Y.
    Ho T.
    Zacholski K.
    Venn C.
    Wages N.A.
    Grant S.
    Maher K.R.
    Medical Oncology, 41 (3)
12345